Blog
RSS FeedPosted by Michael Wonder on 22 Jun 2026
They’re on the PBS but Xavier still can’t access these cancer drugs
20 June 2026 - The eight-year-old and his family will travel to America next month to pick up medicine that is ...
Posted by Michael Wonder on 19 Jun 2026
FDA accepts supplemental biologics license application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
18 June 2026 - Roche announced today that the US FDA has accepted the company’s supplemental biologics license application for Lunsumio ...
Posted by Michael Wonder on 17 Jun 2026
NovaBridge Biosciences receives FDA fast track designation for givastomig in first-line HER2 negative metastatic gastric cancer
16 June 2026 - NovaBridge Biosciences today announced that the US FDA has granted fast track designation to givastomig in combination ...
Posted by Michael Wonder on 16 Jun 2026
Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer
12 June 2026 - Roche announced today that the Ventana PTEN (SP218) RxDx Assay is the first immunohistochemistry companion diagnostic test ...
Posted by Michael Wonder on 15 Jun 2026
Oncopeptides submits type II variation application to EMA for Pepaxti label expansion into third-line treatment
12 June 2026 - Oncopeptides today announces that it has formally submitted its type II variation application to the EMA. ...
Posted by Michael Wonder on 13 Jun 2026
Guardant Health announces FDA approval of Guardant360 CDx as companion diagnostic for Boehringer Ingelheim’s Hernexeos
11 June 2026 - Guardant Health today announced that the US FDA has approved Guardant360 CDx as a companion diagnostic ...
Posted by Michael Wonder on 12 Jun 2026
FDA grants priority review for Genentech’s Tecentriq for a certain type of stage III colon cancer
10 June 2026 - Genentech announced today that the US FDA has accepted the company’s supplemental biologics license application filing for ...
Posted by Michael Wonder on 12 Jun 2026
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
12 June 2026 - Today, the FDA approved belzutifan (Welireg, Merck) in combination with pembrolizumab (Keytruda, Merck) or pembrolizumab and ...
Posted by Michael Wonder on 12 Jun 2026
Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
12 June 2026 - Based on results of CAPItello-281 which prospectively defined PTEN deficient disease and showed Truqap combination reduced risk ...
Posted by Michael Wonder on 11 Jun 2026
Eli Lilly Canada welcome Quebec public reimbursement of Verzenio (abemaciclib) for mBC following successful PCPA negotiation
10 June 2026 - Eli Lilly Canada is pleased to announce that Verzenio (abemaciclib) is now publicly reimbursed in Québec ...
Posted by Michael Wonder on 10 Jun 2026
Imugene's azer-cel granted FDA fast track designation for CLL/SLL and MZL
9 June 2026 - Imugene is pleased to announce that the US FDA has granted fast track designation to azer-cel ...
Posted by Michael Wonder on 07 Jun 2026
Vyloy, Fintepla and Rybrevant move closer to reimbursement after passing HIRA review
5 June 2026 - Several new therapies for serious and rare diseases have moved a step closer to receiving national ...
Posted by Michael Wonder on 05 Jun 2026
First new NHS treatment in over 20 years recommended for women with resistant ovarian cancer
4 June 2026 - The treatment uses a targeted therapy that seeks out a specific protein found on the surface of ...
Posted by Michael Wonder on 05 Jun 2026
US FDA approves FoundationOne CDx as a companion diagnostic for Itovebi (inavolisib) to identify patients with hormone receptor positive, HER2 negative breast cancer with a PIK3CA mutation
2 June 2026 - Foundation Medicine today announced that it has received approval from the US FDA for FoundationOne CDx ...
Posted by Michael Wonder on 05 Jun 2026
J&J Innovative Medicine Korea wins reimbursement for Darzalex SC regimen in newly diagnosed AL amyloidosis
4 June 2026 - Johnson & Johnson Innovative Medicine Korea said Darzalex subcutaneous injection-based quadruple regimen has received reimbursement in ...